Bausch + Lomb Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.1%projected annual EPS growth
Analyst Coverage
12analysts covering
FY Revenue (est.)
$5.5Bnext fiscal year
FY EPS (est.)
$0.80next fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Revenue Quarterly1.2BTarget: 5.42 billion to 5.52 billion USD
Adjusted EBITDA (excluding Acquired IPR&D) Quarterly200MTarget: 1.01 billion to 1.06 billion USD
MIEBO Revenue QuarterlyTarget: Continued double-digit growth and market penetration
Xiidra Revenue QuarterlyTarget: Sustained growth and commercial synergy capture
Watch Items
- Bausch Health Companies (BHC) Separation ProgressTrigger: BHC ownership drops below 80% or final distribution plan is approvedAction: Evaluate tax implications, governance changes, and potential index inclusion catalysts.
- Surgical Segment Margin ExpansionTrigger: Surgical segment operating margin falls below 10%Action: Assess commercial execution of the reorganized account management structure and premium IOL adoption rates.
- Project Halo Bioactive Contact Lens MilestonesTrigger: FDA submission delay beyond 2027Action: Re-evaluate long-term market share projections in the daily silicone hydrogel contact lens market.
Research as of 19 Jun 2026